| |
Sonablate
System Information
Operations
Results
Users
Registry
Clinical Publications
THS
International
Home
Distribution
Information
Contact Information |
|
SONABLATE® 500
What Are the Results?
Over 7,000 men have been
treated for localized prostate cancer with the advanced
Sonablate® 500 HIFU system by over 200 of the top
urologists at over 100 centers worldwide. The system has been
reported by these urologists to perform as follows:
For localized prostate cancer therapy:
|
Patients with Pre-Treat PSA: |
| Less than
10.0ng/ml |
93% |
| 10.0 – 20.0ng/ml |
75% |
|
5- Year Success Rate:
(for all risk
groups) |
77% |
|
Overall Success
Rate:*
*Sonablate®
500 with ver. 4 software and features only |
94% |
|
Presentation by T. Uchida
of Tokai University Hachioji Hospital, Tokyo, Japan at
American Urology Association HIFU Users Meeting 2007
with three year follow-up data of 54 patients. |
For salvage therapy of localized prostate cancer:
| After EBRT: |
| PSA Nadir < 0.5
after 3 months: |
74% success |
| Overall Success
rate: |
78% |
|
Paper published in the British Journal of Urology, March
2008 by M. Emberton, H. Ahmed, R. Illing, et. al.
University College Hospital London, London, England. |
Quality of Life:
Studies show that Quality Of
Life (QOL) factors did not change significantly for patients pre
and post HIFU therapy*
| FACT-G |
Pre: 48.8 |
Post: 50.5 |
| FACT-P |
Pre: 13.5 |
Post: 12.6 |
| IIEF-5 |
Pre: 7.2 |
Post: 6.3 |
|
Poster presentation by T. Uchida of Tokai
University Hachioji Hospital, Tokyo, Japan at Japan Endourology
& ESWL Conference, Okayama, Japan, November 2004. |
Complications:
| Erectile
Dysfunction |
15
– 25% |
| Urethral
Stricture |
6
– 25% |
| Incontinence |
1
– 11% |
| Urinary Tract
Infections |
0
– 10% |
| Retrograde
Ejaculation |
0
– 9% |
| Epididymitis |
0
– 6% |
| Recto-urethral
Fistula |
0
– 3% |
|
Best and most severe
range of complications taken from T. Uchida, “Five Years
Experience of Transrectal High-Intensity Focused
Ultrasound Using the Sonablate Device in the Treatment
of Localized Prostate Cancer”, in the “International
Journal of Urology”, Vol. 13 No. 3 March 2006, and M.
Emberton, “Sonablate 500 Transrectal High-Intensity
Focused Ultrasound for the Treatment of Localized
Prostate Cancer” in “Expert Review of Medical Devices”
March 2006. |
|
|